Georgia Salanti
Overview
Explore the profile of Georgia Salanti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
256
Citations
19666
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneider-Thoma J, Hamza T, Chalkou K, Siafis S, Dong S, Bighelli I, et al.
Lancet Psychiatry
. 2025 Mar;
PMID: 40023172
Background: Clozapine is recommended by national and international guidelines for people with treatment-resistant schizophrenia. However, available meta-analyses of randomised controlled trials have not shown superior efficacy of clozapine when compared...
2.
Siafis S, Nomura N, Schneider-Thoma J, Bighelli I, Bannach-Brown A, Ramage F, et al.
F1000Res
. 2025 Jan;
13:1017.
PMID: 39844929
Background: Muscarinic receptor agonism and positive allosteric modulation is a promising mechanism of action for treating psychosis, not present in most D2R-blocking antipsychotics. Xanomeline, an M1/M4-preferring agonist, has shown efficacy...
3.
Smith K, Boyce N, Chevance A, Chiocchia V, Correll C, Donoghue K, et al.
Br J Psychiatry
. 2024 Dec;
:1-9.
PMID: 39710623
Background: Trace amine-associated receptor 1 (TAAR1) agonists offer a new approach, but there is uncertainty regarding their effects, exact mechanism of action and potential role in treating psychosis. Aims: To...
4.
Radojewski P, Piredda G, Bonanno G, Lovblad K, Vargas M, Sutter R, et al.
Eur J Neurol
. 2024 Dec;
32(1):e16557.
PMID: 39676509
Background: Ultra-high-field magnetic resonance imaging (MRI) at a field strength of 7 Tesla (T) has marked a significant milestone in diagnostic imaging since it was approved for clinical use in...
5.
Feber L, Peter N, Chiocchia V, Schneider-Thoma J, Siafis S, Bighelli I, et al.
JAMA Psychiatry
. 2024 Oct;
82(1):47-56.
PMID: 39412783
Importance: Cognitive deficits are a substantial part of the symptoms of schizophrenia spectrum disorders (SSDs) and contribute heavily to the burden of disease. Antipsychotic drugs are not cognitive enhancers, but...
6.
Nourredine M, Jurek L, Salanti G, Cipriani A, Subtil F, Efthimiou O, et al.
Syst Rev
. 2024 Oct;
13(1):256.
PMID: 39396049
Background: Attention-deficit/hyperactivity disorder (ADHD) affects approximately 5% of children globally, with symptoms often persisting into adulthood. While pharmacological interventions are commonly employed for management, understanding the optimal dosing for efficacy...
7.
Feber L, Salanti G, Harrer M, Salahuddin N, Hansen W, Priller J, et al.
F1000Res
. 2024 Sep;
13:649.
PMID: 39238833
Introduction: Treating the early phase of schizophrenia is crucial for preventing further episodes and improving quality of life, functioning, and social inclusion. Pharmacotherapies are first-line treatments, but have limitations. There...
8.
Efthimiou O, Seo M, Chalkou K, Debray T, Egger M, Salanti G
BMJ
. 2024 Sep;
386:e078276.
PMID: 39227063
No abstract available.
9.
Hamza T, Schwarzer G, Salanti G
BMC Med Res Methodol
. 2024 Aug;
24(1):169.
PMID: 39103781
Background: Although aggregate data (AD) from randomised clinical trials (RCTs) are used in the majority of network meta-analyses (NMAs), other study designs (e.g., cohort studies and other non-randomised studies, NRS)...
10.
Siafis S, Wu H, Nomura N, Schneider-Thoma J, Bighelli I, Lorenz C, et al.
Syst Rev
. 2024 Aug;
13(1):205.
PMID: 39095865
Background: Severe psychomotor agitation and aggression often require immediate pharmacological intervention, but clear evidence-based recommendations for choosing among the multiple options are lacking. To address this gap, we plan a...